Last updated: 2026-09-16 11:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Longeveron Inc. (LGVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.20, with a market capitalisation of $22.06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.75 to $12.30. This page covers its latest market performance, valuation, price trends and company information.
$22.06M | |
$7.10 | |
$4,500.00 | |
$4.75 | |
$6.86 | |
2.00 | |
46.03K | |
-- | |
$12.30 | |
$4.75 | |
-- | |
-- |
Longeveron Inc. (LGVN) is trading at $7.20 in pre-market trading as of 2026-09-16 11:03:00, up 4.90% ($0.34) from the previous close of $6.86
Pre-market trading shows how investors are pricing LGVN before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Longeveron Inc. (LGVN) moved from $6.81 to $7.20, representing a gain of 5.67% ($0.39).
The stock traded between $6.50 and $7.60 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 50.71 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 32.4%
LGVN is currently trading at $7.20, placing it 32.4% of the way from its 52-week low of $4.75 to its 52-week high of $12.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 38 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Longeveron Inc. (LGVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.